A Q&A with Douglas Hoey, CEO of NCPA, on how the new provision from CMS requiring DIR fees at the point of sale is impacting independent pharmacies in 2024.
Eric Fromhart, co-founder and chief growth officer at Aventi Health, talked about the importance of the 340B drug pricing program at the 2024 AAP annual conference.
Drug Topics sat down with Douglas Hoey, CEO of NCPA, at the 2024 AAP annual conference to discuss how independent pharmacies are doing so far this year.
This week, a divided America watched as the Supreme Court heard oral arguments regarding whether to reinstate restrictions on accessing mifepristone, an essential drug used in medication abortion.